Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jinfukang oral liquid plus first-line chemotherapy for advanced non-small cell lung cancer
ChiCTR1900022253Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of jinfukang in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Quality of life. Started Apr 2019; status: recruiting.
02
Drugs
jinfukang
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900022253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022253.